, Volume 3, Issue 1, pp 30-37

Recent peginterferon and ribavirin combination trials

Purchase on Springer.com

$39.95 / €34.95 / £29.95*

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Peginterferon alpha and ribavirin combination is the recommended first choice therapeutic regimen for chronic hepatitis C. Therapy duration and ribavirin dose are individualized according to the hepatitis C virus genotype. Patients with genotype 1 require 48-week courses with the usual ribavirin doses, whereas 24-week courses with lower ribavirin doses are sufficient for patients with genotype 2/3. In patients with genotype 1, the absence of an early (week 12) virologic response means no chance for sustained response and signals therapy discontinuation.